Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 1 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 46Thoracic 34Breast 28Gynecologic 20Head & Neck 17Other hematologic neoplasm 13Lymphoid 13Genitourinary 9CNS 4Tumor-Agnostic 3Plasma cell 2Other solid neoplasm 2Dermatologic 2Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 2Renal Insufficiency 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 177Bortezomib 98Lenalidomide 90daratumumab 46Melphalan 45Thalidomide 44pomalidomide 42Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14ixazomib 11isatuximab 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Drug Therapy × Plasma cell × Clear all
NCT02288741 2014-11-11

DSMM-II

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 3 Completed
549 enrolled
Plasma cell

Multiple Myeloma

NCT00416897 2013-08-26

Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure

National Cancer Institute (NCI)

Phase 3 Completed
280 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡